Sponsors (3)
Official title: To amend the Federal Food, Drug, and Cosmetic Act to enhance medical device communications and ensure device cleanliness.
Introduced March 26, 2025 by Ted Lieu · Last progress March 26, 2025
The bill strengthens FDA oversight and cross-border reporting to improve device safety and standardized reprocessing, but it raises compliance costs, risks product shortages or delays, and may slow some beneficial device changes—trading faster safety oversight for higher industry burden and potential access impacts.
Hospitals, clinicians, and patients will receive earlier federal notice and faster FDA action on device design/reprocessing changes and foreign safety communications, reducing exposure to unsafe devices and enabling quicker national guidance.
Manufacturers face stronger regulatory incentives and an enforcement mechanism (adulteration classification) to report safety-relevant changes and foreign communications, improving corporate accountability and consistency of safety information.
Hospitals, clinics, and patients benefit from standardized, validated instructions and rapid-assessment test validation for reusable-device reprocessing, which should lower infection risk and improve safe device reuse practices.
Device manufacturers (including small firms) will face materially higher compliance, legal, and administrative costs to prepare and submit pre-change notices and rapid foreign-communication reports (including a short 5-day window), increasing business burdens and likely contributing to higher device prices.
Aggressive use of 'adulterated' designations, reporting lapses, or stricter validation rules could trigger recalls or temporary shortages of devices and rapid-assessment tests, disrupting supply and limiting patient and provider access.
The new notification and validation requirements (and related timelines) may slow the timely implementation of beneficial device improvements or updated reprocessing instructions, delaying access to potentially better or safer technology for clinicians and patients.
Based on analysis of 4 sections of legislative text.
Requires pre-change written notice and rapid reporting for device design/reprocessing changes, expands device definition to cover rapid reprocessing tests, and mandates validation data for listed tests.
Requires medical device manufacturers to notify HHS/FDA in writing before making design or reprocessing-instruction changes for devices sold in interstate commerce and to report when they widely share information about such changes or safety concerns with foreign health providers; failure to comply can make a device “adulterated.” Expands the device definition to cover rapid assessment tests that verify proper reprocessing of reusable devices, defines “reusable device,” and directs HHS to publish a list (within one year) of rapid assessment test types that must include validated instructions and validation data with notifications.